{"disease":{"id":"esophageal-squamous-cell-neoplasm","name":"esophageal squamous cell neoplasm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03183115","title":"RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"E-DA Hospital","has_results":false},{"nct_id":"NCT05287880","title":"Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Fifth Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04221893","title":"Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04501913","title":"Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04460937","title":"Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03223662","title":"Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}